Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Science (New York, N.Y.)|November 14, 2015
Evidence for primordial water in Earth's deep mantleLydia J Hallis, Gary R Huss, Kazuhide Nagashima, et al.
Science (New York, N.Y.)|September 5, 1997
Detection of soft X-rays and a sensitive search for noble gases in comet Hale-BoppV A Krasnopolsky, M J Mumma, M Abbott, et al.
Clinical Immunology (Orlando, Fla.)|June 23, 2004
Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cellsJaime F Modiano, Juan Sun, Julie Lang, et al.
Cancer Biology & Therapy|June 25, 2013
Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancerChandra P Belani, John J Nemunaitis, Abraham Chachoua, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 9, 2024
Two distinct populations of dark comets delineated by orbits and sizesDarryl Z Seligman, Davide Farnocchia, Marco Micheli, et al.
Journal of the National Cancer Institute|July 19, 2011
Opportunities and challenges in the development of experimental drug combinations for cancerRachel W Humphrey, Laura M Brockway-Lunardi, David T Bonk, et al.
Science (New York, N.Y.)|March 3, 1995
The Hubble Space Telescope (HST) observing campaign on comet Shoemaker-Levy 9H A Weaver, M F A'Hearn, C Arpigny, et al.
American Journal of Clinical Pathology|April 15, 2004
Assessment of t(2;5)(p23;q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphomaXiayuan Liang, Sandra J Meech, Lorrie F Odom, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2011
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancerC Manegold, N van Zandwijk, A Szczesna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2011
Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancerVera Hirsh, Luis Paz-Ares, Michael Boyer, et al.
Pageof 5